Icu Stay Articles & Analysis: Older
17 news found
Patients experienced immediate hemodynamic and symptom improvement with modest hospital resource burden, demonstrated by minimal need for adjunctive therapy and a median post procedure ICU stay of 0 days. All-cause mortality was only 0.8% at 30 days. “These results, in a large patient population spanning 50 sites, further reinforce the strong safety ...
Fouling of endotracheal tubes is associated with an increased risk of respiratory complications, increased antibiotic usage, infection and longer stays in the ICU. The clinical studies received the requisite ethics approvals from Health Canada and Western IRB prior to commencement in December 2018. ...
By inhibiting the activity of these digestive proteases, LB1148 has the potential to prevent damage to GI tissues, accelerate the time to the return of normal GI function, and shorten the duration of costly post-surgery hospital stays. About Palisade Bio Palisade Bio is a clinical stage biopharmaceutical company advancing therapies that aid patients suffering with acute and ...
By inhibiting the activity of these digestive proteases, LB1148 has the potential to prevent damage to GI tissues, accelerate the time to the return of normal GI function, and shorten the duration of costly post-surgery hospital stays. The U.S. FDA has granted Fast Track designation to LB1148 for two clinical indications: reduction of adhesions following abdominal or pelvic ...
Positive data from Phase 2 clinical trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in the return of bowel function and a decrease in the length of stay in ICU and hospital compared to placebo. Plans are underway to commence a pivotal, Phase 3 study of LB1148 in the second half of 2022. ...
By inhibiting the activity of these digestive proteases, LB1148 has the potential to prevent damage to GI tissues, accelerate the time to return of normal GI function, and shorten the duration of costly post-surgery hospital stays. About Palisade Bio Palisade Bio is a clinical stage biopharmaceutical company advancing therapies that aid patients suffering with acute and ...
By inhibiting the activity of these digestive proteases, LB1148 has the potential to prevent damage to GI tissues, accelerate the time to return of normal GI function, and shorten the duration of costly post-surgery hospital stays. About Palisade Bio Palisade Bio is a clinical stage biopharmaceutical company advancing therapies that help patients with acute and chronic ...
Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications ...
Positive data from Phase 2 trials of LB1148 demonstrated safety and tolerability as well as a statistically significant improvement in return to bowel function and decrease in length of stay in ICU and hospital compared to placebo. Palisade Bio believes that its investigational therapies have the potential to address the myriad health conditions and complications ...
Despite unfavorable donor and recipient characteristics in the [Paragonix] cohort of patients, early clinical outcomes including Intensive Care Unit length of stay are improved.” The investigators reported that the donor hearts preserved by the Paragonix SherpaPak had statistically significant increases in total ischemic time and travel distance. ...
In the pooled analysis: Median ventilation duration and ICU length of stay in the total study population were 10 versus 52 (P = 0.07), and 12 versus 54 (P = 0.03) days for the intervention versus sham group. ...
Rapid elimination of infected monocytes in COVID-19 patients could reduce ICU stays and decrease longterm lung damage. NKT mobilization could also provide long-term T-cell immunity. ...
Current treatment options are not well-studied and often require invasive surgeries and prolonged stays in the ICU.” Patients often present with focal neurological symptoms, non-focal cognitive symptoms or generalized dysfunction. ...
Two pilot randomized controlled trials, recently completed in Europe and Australia, indicated that compared with placebo stimulation, the VentFree may reduce ventilation duration and ICU length of stay. Last year VentFree™ received FDA Breakthrough Device Designation and CE marking in the European Union. ...
Liberate published the results of its pilot trial of VentFree in July, which found a shorter ventilation duration and ICU length of stay in patients who received VentFree compared with standard of care. ...
In addition, the Tempo Lead allows patients to ambulate sooner after procedures such as TAVR and TMVR, accelerating recovery times, and enabling patient transfer directly to a step-down or telemetry unit instead of an ICU or CCU. Cleared by the U.S. FDA in October 2016, the Tempo Lead is the only active fixation temporary pacing lead available in the world. ...
In addition, the Tempo Lead allows patients to ambulate sooner after procedures such as TAVR and TMVR, accelerating recovery times, and enabling patient transfer directly to a step-down or telemetry unit instead of an ICU or CCU. Cleared by the U.S. FDA in October 2016, the Tempo Lead is the only active fixation temporary pacing lead available in the world. ...